Compare · NVS vs VERA
NVS vs VERA
Side-by-side comparison of Novartis AG (NVS) and Vera Therapeutics Inc. (VERA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVS and VERA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $292.65B, about 98.2x VERA ($2.98B).
- Over the past year, NVS is up 24.2% and VERA is up 81.3% - VERA leads by 57.1 points.
- VERA has been more active in the news (8 items in the past 4 weeks vs 1 for NVS).
- NVS has more recent analyst coverage (25 ratings vs 18 for VERA).
- Company
- Novartis AG
- Vera Therapeutics Inc.
- Price
- $150.34-1.97%
- $43.10+3.85%
- Market cap
- $292.65B
- $2.98B
- 1M return
- -2.34%
- +28.37%
- 1Y return
- +24.17%
- +81.27%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 1
- 8
- Recent ratings
- 25
- 18
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Vera Therapeutics Inc.
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Latest NVS
- The Quest to Repair What Multiple Sclerosis Takes Away
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- Novartis AG upgraded by Argus with a new price target
- Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
- SEC Form S-8 filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form IRANNOTICE filed by Novartis AG
Latest VERA
- Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- PRESIDENT AND CEO Fordyce Marshall sold $1,956,187 worth of shares (46,250 units at $42.30) as part of a pre-agreed trading plan, decreasing direct ownership by 23% to 151,994 units (SEC Form 4)
- Vera Therapeutics Inc. filed SEC Form 8-K: Leadership Update
- Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner
- FDA Approval for TRUTAKNA issued to VERA THERAPEUTICS INC.
- Vera Therapeutics Inc. filed SEC Form 8-K: Other Events
- Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathy
- PRESIDENT AND CEO Fordyce Marshall sold $701,769 worth of shares (18,500 units at $37.93) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 198,244 units (SEC Form 4)
- Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Vera Therapeutics Inc. filed SEC Form 8-K: Other Events